tetano
Editor, Senior Moderator
Sci Rep
. 2022 Mar 10;12(1):3890.
doi: 10.1038/s41598-022-07793-1.
Anti-SARS-CoV-2 equine F (Ab') [SUB]2[/SUB] immunoglobulin as a possible therapy for COVID-19
Viviane Fongaro Botosso[SUP] #[/SUP][SUP] 1 [/SUP], Soraia Attie Calil Jorge[SUP] #[/SUP][SUP] 2 [/SUP], Renato Mancini Astray[SUP] #[/SUP][SUP] 3 [/SUP], Ana Marcia de Sá Guimarães[SUP] #[/SUP][SUP] 4 [/SUP], Monica Beatriz Mathor[SUP] #[/SUP][SUP] 5 [/SUP], Patrícia Dos Santos de Carneiro[SUP] #[/SUP][SUP] 6 [/SUP], Edison Luiz Durigon[SUP] 4 [/SUP], Dimas Covas[SUP] 7 [/SUP], Danielle Bruna Leal de Oliveira[SUP] 1 4 [/SUP], Ricardo das Neves Oliveira[SUP] 8 [/SUP], Durvanei Augusto Maria[SUP] 9 [/SUP], Silas Fernandes Eto[SUP] 9 [/SUP], Neuza Maria Frazatti Gallina[SUP] 10 [/SUP], Giselle Pidde[SUP] 11 [/SUP], Carla Cristina Squaiella-Baptistão[SUP] 11 [/SUP], Dilza Trevisan Silva[SUP] 12 [/SUP], Isadora Maria Villas-Boas[SUP] 11 [/SUP], Dayanne Carla Fernandes[SUP] 11 [/SUP], Aline Vivian Vatti Auada[SUP] 8 [/SUP], Alexandre Campos Banari[SUP] 4 [/SUP], Antônio Francisco de Souza Filho[SUP] 4 [/SUP], Camila Bianconi[SUP] 8 [/SUP], Carla Lilian de Agostini Utescher[SUP] 1 [/SUP], Denise Cristina André Oliveira[SUP] 1 [/SUP], Douglas Oscar Ceolin Mariano[SUP] 8 [/SUP], Flávia Ferreira Barbosa[SUP] 3 [/SUP], Giuliana Rondon[SUP] 9 [/SUP], Josana Kapronezai[SUP] 1 [/SUP], Juliana Galvão da Silva[SUP] 6 [/SUP], Mauricio Barbugiani Goldfeder[SUP] 9 [/SUP], Priscila Comone[SUP] 8 [/SUP], Regis Edgar Castilho Junior[SUP] 9 [/SUP], Taiana Tainá Silva Pereira[SUP] 4 [/SUP], Fan Hui Wen[SUP] 13 [/SUP], Denise V Tambourgi[SUP] 14 [/SUP], Ana Marisa Chudzinski-Tavassi[SUP] 15 16 [/SUP]
Affiliations
Abstract
The new outbreak of coronavirus disease 2019 (COVID-19) has infected and caused the death of millions of people worldwide. Intensive efforts are underway around the world to establish effective treatments. Immunoglobulin from immunized animals or plasma from convalescent patients might constitute a specific treatment to guarantee the neutralization of the virus in the early stages of infection, especially in patients with risk factors and a high probability of progressing to severe disease. Worldwide, a few clinical trials using anti-SARS-CoV-2 immunoglobulins from horses immunized with the entire spike protein or fragments of it in the treatment of patients with COVID-19 are underway. Here, we describe the development of an anti-SARS-CoV-2 equine F(ab')[SUB]2[/SUB] immunoglobulin using a newly developed SARS-CoV-2 viral antigen that was purified and inactivated by radiation. Cell-based and preclinical assays showed that the F(ab')[SUB]2[/SUB] immunoglobulin successfully neutralizes the virus, is safe in animal models, and reduces the severity of the disease in a hamster model of SARS-CoV-2 infection and disease.
. 2022 Mar 10;12(1):3890.
doi: 10.1038/s41598-022-07793-1.
Anti-SARS-CoV-2 equine F (Ab') [SUB]2[/SUB] immunoglobulin as a possible therapy for COVID-19
Viviane Fongaro Botosso[SUP] #[/SUP][SUP] 1 [/SUP], Soraia Attie Calil Jorge[SUP] #[/SUP][SUP] 2 [/SUP], Renato Mancini Astray[SUP] #[/SUP][SUP] 3 [/SUP], Ana Marcia de Sá Guimarães[SUP] #[/SUP][SUP] 4 [/SUP], Monica Beatriz Mathor[SUP] #[/SUP][SUP] 5 [/SUP], Patrícia Dos Santos de Carneiro[SUP] #[/SUP][SUP] 6 [/SUP], Edison Luiz Durigon[SUP] 4 [/SUP], Dimas Covas[SUP] 7 [/SUP], Danielle Bruna Leal de Oliveira[SUP] 1 4 [/SUP], Ricardo das Neves Oliveira[SUP] 8 [/SUP], Durvanei Augusto Maria[SUP] 9 [/SUP], Silas Fernandes Eto[SUP] 9 [/SUP], Neuza Maria Frazatti Gallina[SUP] 10 [/SUP], Giselle Pidde[SUP] 11 [/SUP], Carla Cristina Squaiella-Baptistão[SUP] 11 [/SUP], Dilza Trevisan Silva[SUP] 12 [/SUP], Isadora Maria Villas-Boas[SUP] 11 [/SUP], Dayanne Carla Fernandes[SUP] 11 [/SUP], Aline Vivian Vatti Auada[SUP] 8 [/SUP], Alexandre Campos Banari[SUP] 4 [/SUP], Antônio Francisco de Souza Filho[SUP] 4 [/SUP], Camila Bianconi[SUP] 8 [/SUP], Carla Lilian de Agostini Utescher[SUP] 1 [/SUP], Denise Cristina André Oliveira[SUP] 1 [/SUP], Douglas Oscar Ceolin Mariano[SUP] 8 [/SUP], Flávia Ferreira Barbosa[SUP] 3 [/SUP], Giuliana Rondon[SUP] 9 [/SUP], Josana Kapronezai[SUP] 1 [/SUP], Juliana Galvão da Silva[SUP] 6 [/SUP], Mauricio Barbugiani Goldfeder[SUP] 9 [/SUP], Priscila Comone[SUP] 8 [/SUP], Regis Edgar Castilho Junior[SUP] 9 [/SUP], Taiana Tainá Silva Pereira[SUP] 4 [/SUP], Fan Hui Wen[SUP] 13 [/SUP], Denise V Tambourgi[SUP] 14 [/SUP], Ana Marisa Chudzinski-Tavassi[SUP] 15 16 [/SUP]
Affiliations
- PMID: 35273234
- PMCID: PMC8913704
- DOI: 10.1038/s41598-022-07793-1
Abstract
The new outbreak of coronavirus disease 2019 (COVID-19) has infected and caused the death of millions of people worldwide. Intensive efforts are underway around the world to establish effective treatments. Immunoglobulin from immunized animals or plasma from convalescent patients might constitute a specific treatment to guarantee the neutralization of the virus in the early stages of infection, especially in patients with risk factors and a high probability of progressing to severe disease. Worldwide, a few clinical trials using anti-SARS-CoV-2 immunoglobulins from horses immunized with the entire spike protein or fragments of it in the treatment of patients with COVID-19 are underway. Here, we describe the development of an anti-SARS-CoV-2 equine F(ab')[SUB]2[/SUB] immunoglobulin using a newly developed SARS-CoV-2 viral antigen that was purified and inactivated by radiation. Cell-based and preclinical assays showed that the F(ab')[SUB]2[/SUB] immunoglobulin successfully neutralizes the virus, is safe in animal models, and reduces the severity of the disease in a hamster model of SARS-CoV-2 infection and disease.